Literature DB >> 24788242

Barraquer-Simons syndrome: a rare clinical entity.

Pelin Ozlem Simsek-Kiper1, Emir Roach, Gulen Eda Utine, Koray Boduroglu.   

Abstract

The Barraquer-Simons syndrome or acquired parital lipodystrophy is a rare form of partial lipodystrophy characterized by gradual onset of bilaterally symmetrical subcutaneous fat loss from the face, neck, upper extremities, thorax, and abdomen but sparing the lower extremities. The patients gradually loose their subcutaneous fat in clearly demarcated, generally symmetric areas of the body over several years. Nephropathy, myopathy, deafness, epilepsy, and intellectual disability have also been described. Although the etiology is unknown, heterozygous mutations in the gene encoding one of the nuclear lamina proteins, lamin B2, have been reported in several patients. We here report on a young female patient affected by Barraquer-Simons syndrome, without accompanying renal or central nervous system involvement in whom DNA sequencing did not reveal any mutations in the genes LMNB2, LMNA, PPARG, AGPAT2, BSCL2, CAV1, PTRF, PLIN1, and CIDEC.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Barraquer-Simons syndrome; LMNB2; loss of subcutaneous fat tissue; partial lipodystrophy

Mesh:

Substances:

Year:  2014        PMID: 24788242     DOI: 10.1002/ajmg.a.36491

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

1.  Barraquer-Simons syndrome: a unique patient's perspective on diagnosis, disease progression and recontouring treatment.

Authors:  Lene Nyhøj Heidemann; Jørn Bo Thomsen; Jens Ahm Sørensen
Journal:  BMJ Case Rep       Date:  2016-07-11

Review 2.  Progressive hemifacial atrophy: a review.

Authors:  Stanislav N Tolkachjov; Nirav G Patel; Megha M Tollefson
Journal:  Orphanet J Rare Dis       Date:  2015-04-01       Impact factor: 4.123

3.  Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome): Early Cosmetic Intervention with Autologous Fat.

Authors:  Nark-Kyoung Rho; Won-Serk Kim
Journal:  Ann Dermatol       Date:  2018-08-28       Impact factor: 1.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.